<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373565">
  <stage>Registered</stage>
  <submitdate>11/09/2017</submitdate>
  <approvaldate>19/09/2017</approvaldate>
  <actrnumber>ACTRN12617001334392</actrnumber>
  <trial_identification>
    <studytitle>Methoxyflurane metabolite (fluoride) presence in ambulance staff</studytitle>
    <scientifictitle>Change in methoxyflurane metabolite (fluoride) presence in ambulance staff</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fluoride accumulation</healthcondition>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Health service research</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Emergency Medical Technicians in a metropolitan ambulance service will be using Penthrox (methoxyflurane) following newly introduced operational guidelines, occasionally administering up to 6mL to each patient as needed for pain relief. We expect they will be exposed to trace vapour (quantity not known) and that this may result in elevated serum fluoride in those staff. We will observe their serum fluoride over the course of 24 months to identify whether there is any evidence of fluoride accumulation.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Early Detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Statistically significant changes in serum fluoride concentration.
Serum fluoride will be measured by ion specific electrode in buffered venous sample.</outcome>
      <timepoint>Methoxyflurane administration by ambulance staff will commence from June 2017, following an organisational implementation plan. We will measure staff serum fluoride at 0 months after introduction (during June 2017) to establish a baseline, and at 1, 4, 8, 12, 18 and 24 (primary endpoint) months after introduction of methoxyflurane into clinical practice.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of change in serum fluoride concentration recorded over safe levels (&lt;= 40 µmol/L).</outcome>
      <timepoint>0, 1, 4, 8, 12, 18 and 24 months following introduction of methoxyflurane into clinical practice, as described for the primary endpoint.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Ambulance officers rostered in full time patient contact role. Preferential recruitment of Emergency Medical Technicians over other qualifications.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Staff members expected to leave the ambulance service in the course of the trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Sample size 12 chosen to achieve 95% power to detect a 1 µmol/L difference in serum fluoride with p &lt; 0.01, with up to 50% attrition due to change in role/injury or illness/cessation of employment/opting out.
Measures of change in blood fluoride over time will be calculated, including 95% confidence intervals of mean at each month tested, a series of one-sample t-tests of change in group mean vs. initial and vs. previous month (considering p &lt; 0.05 as statistically significant), and regression models for change in blood fluoride over time.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>1/06/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/07/2017</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>12</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. Paul Docherty</primarysponsorname>
    <primarysponsoraddress>University of Canterbury
Private Bag 4800
Christchurch 8140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Science Challenge funding (MBIE)</fundingname>
      <fundingaddress>Callaghan Innovation campus
69 Gracefield Rd
Gracefield
Wellington 5010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Medtec CORE (TEC)</fundingname>
      <fundingaddress>The University of Auckland
Private Bag 92019
Auckland 1142
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Serah Allison</sponsorname>
      <sponsoraddress>c/o Wellington Free Ambulance
PO Box 601
Wellington 6140</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Dirk Pons</othercollaboratorname>
      <othercollaboratoraddress>University of Canterbury
Private Bag 4800
Christchurch 8140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. J Geoffrey Chase</othercollaboratorname>
      <othercollaboratoraddress>University of Canterbury
Private Bag 4800
Christchurch 8140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>One option that ambulance staff have at their disposal for managing patient pain is Penthrox (methoxyflurane), which produces a vapour that the patient inhales. Research of one-off Penthrox doses indicate that the drug is safe. However ambulance staff will be repeatedly exposed to trace quantities of vapour over months and years of treating patients. Methoxyflurane can cause raised blood fluoride level, and if these levels become high enough it can be toxic. We are observing ambulance staff over a prolonged period to determine whether or not their blood fluoride level increases to dangerous levels over time.</summary>
    <trialwebsite>None</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Canterbury Human Ethics Committee</ethicname>
      <ethicaddress>University of Canterbury
Private Bag 4800
Christchurch 8140</ethicaddress>
      <ethicapprovaldate>23/05/2017</ethicapprovaldate>
      <hrec>HEC 2017/23/LR</hrec>
      <ethicsubmitdate>24/04/2017</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Serah Allison</name>
      <address>Wellington Free Ambulance
PO Box 601
Wellington 6140</address>
      <phone>+64 27 486 6707</phone>
      <fax />
      <email>serah.allison@pg.canterbury.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Serah Allison</name>
      <address>Wellington Free Ambulance
PO Box 601
Wellington 6140</address>
      <phone>+64 27 486 6707</phone>
      <fax />
      <email>serah.allison@pg.canterbury.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Serah Allison</name>
      <address>Wellington Free Ambulance
PO Box 601
Wellington 6140</address>
      <phone>+64 27 486 6707</phone>
      <fax />
      <email>serah.allison@pg.canterbury.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Serah Allison</name>
      <address>Wellington Free Ambulance
PO Box 601
Wellington 6140</address>
      <phone>+64 27 486 6707</phone>
      <fax />
      <email>serah.allison@pg.canterbury.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>